“The kinds of biotechs best for investors who aren’t huge risk-takers are those that generate solid revenue growth, are profitable (or soon will be), and have promising pipelines,” advises the author of today’s article, who proceeds to highlight three stocks that appear to match this profile to consider buying this month. For more, CLICK HERE.
Trillium Therapeutics surged 1,330% last year – and as an immuno-oncology company, its performance had nothing to do with COVID-19 related catalysts. Moreover, its 2020 run may have just been the beginning, as the company’s cancer-fighting candidates – which it hopes will ultimately replace chemotherapy as the dominant type of cancer treatment – are, as today’s article explains, currently in…
Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK…
The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise…
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…
What’s behind biotech’s recent underperformance? One important factor may be the impending presidential election – and as one exchange-traded fund strategist cited in today’s article explains, “…if history repeats, this pullback may represent an attractive buying opportunity.” What does the history of biotech’s performance leading up to and following presidential elections suggest about buying the biotech dip? CLICK HERE.
The biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that…